Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06839872 | NOT YET RECRUITING | Chronic Lymphocytic Leukemia

A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor:

AstraZeneca

Brief Summary:

To assess the efficacy and safety of pirtobrutinib in participants with CLL/SLL who have progressed on first-line treatment with acalabrutinib.

Condition or disease

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Intervention/treatment

Pirtobrutinib

Acalabrutinib

Phase

PHASE2

Detailed Description:

The purpose of this study is to assess the efficacy and safety of pirtobrutinib in participants with CLL/SLL who have progressed on first-line treatment with acalabrutinib. A subset of participants who have disease progression on pirtobrutinib will be retreated with acalabrutinib to assess whether relapsed CLL can be re-sensitized to a covalent irreversible BTK inhibitor such as acalabrutinib, and thereby, remain on treatment within the BTK inhibitor class rather than transition into another CLL/SLL treatment. * The study duration for each participant will be up to 3 years in total. * For participants who receive pirtobrutinib alone, the visit frequency will be approximately every month for the first 6 months. After that, the visit frequency will be reduced to one visit approximately every 3 months for the subsequent 12 months. The final part of the Treatment Phase has 2 visits in the space of 6 months. There is one visit to the site after the Treatment Phase. * Participants who have disease progression on pirtobrutinib and go on to receive acalabrutinib retreatment will visit the site approximately once every month for the first 6 months. After that, the visit frequency will be reduced to 2 visits in the space of 6 months. There is one visit to the site after the Treatment Phase.

Study Type : INTERVENTIONAL
Estimated Enrollment : 60 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : BOSS: BTK Inhibitor Optimal Sequencing Study Phase II Open-label Single Arm Trial of Pirtobrutinib in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma After First-line Acalabrutinib Progression
Actual Study Start Date : 2025-06-30
Estimated Primary Completion Date : 2028-07-28
Estimated Study Completion Date : 2030-07-29

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 110 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Participant must be ≥ 18 at the time of signing the informed consent.
  • * Participants must have received acalabrutinib monotherapy as first-line treatment for CLL/SLL, have progressed per the iwCLL Criteria (Hallek et al 2018) and be eligible for second-line treatment by the same criteria.
  • * ECOG performance status of 0, 1, or 2.
  • * Adequate organ and BM function.
  • * Adequate coagulation, defined as aPTT or PTT and PT or INR not greater than 1.5 × ULN.
  • * Participants have a clearly defined, documented and accessible start date of their first line acalabrutinib monotherapy for CLL/SLL.
  • * Participants are eligible for the acalabrutinib retreatment phase only if they have progressed on pirtobrutinib monotherapy per iwCLL Criteria.
Exclusion Criteria
  • * Major surgical procedure within 30 days before and not recovered adequately the first dose of study drug.
  • * Participants who experienced a major bleeding event or Grade ≥ 3 arrhythmia on prior treatment with a BTK inhibitor.
  • * History of bleeding diathesis (eg, hemophilia, von Willebrand disease).
  • * History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
  • * Significant cardiovascular disease.
  • * History of PML.
  • * Any active significant infection.
  • * HIV positive
  • * Active HBV or HCV infection.
  • * Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression.
  • * Active auto-immune cytopenia.
  • * History of prior or current malignancy.
  • * Requires or receiving therapeutic anticoagulation with warfarin or equivalent vitamin K antagonists.
  • * Received a live virus vaccination within 28 days of first dose of study drug.
  • * Requires treatment with a strong CYP3A inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited.
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Location Details

NCT06839872

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

United States, Florida

Research Site

Saint Petersburg, Florida, United States, 33709

Not yet recruiting

United States, Iowa

Research Site

Ames, Iowa, United States, 50010

Not yet recruiting

United States, Maryland

Research Site

Baltimore, Maryland, United States, 21201

Not yet recruiting

United States, North Carolina

Research Site

Charlotte, North Carolina, United States, 28204

Not yet recruiting

United States, North Carolina

Research Site

Winston-Salem, North Carolina, United States, 27103

Not yet recruiting

United States, Ohio

Research Site

Columbus, Ohio, United States, 43210

Not yet recruiting

United States, Oregon

Research Site

Medford, Oregon, United States, 97504

Not yet recruiting

United States, Tennessee

Research Site

Nashville, Tennessee, United States, 37203

Not yet recruiting

United States, Virginia

Research Site

Charlottesville, Virginia, United States, 22908

Not yet recruiting

United States, Virginia

Research Site

Richmond, Virginia, United States, 23219

Not yet recruiting

United States, Washington

Research Site

Seattle, Washington, United States, 98109

Not yet recruiting

United States, Washington

Research Site

Spocane, Washington, United States, 99208

Not yet recruiting

United States, Washington

Research Site

Tacoma, Washington, United States, 98405